Evaluation of para-aortic nodal dissection for locoregionally advanced gastric cancer with 1-3 involved para-aortic nodes

Chinese Medical Journal

Volumn 127, Issue 3, 2014, Pages 435-441

  Zhang, Chang Hua ^a,b   He, Yu Long ^a,b   Schwarz, Roderich E ^c   Smith, David D ^d   Wang, Liang ^a,b   Liu, Fa Keng ^a,b   Zhan, Wen Hua ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Gastric cancer; Lymphadenectomy; Para aortic node; Prognosis

Indexed keywords

ADULT; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; FEMALE; FOLLOW UP; GASTRECTOMY; HAZARD RATIO; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PANCREAS FISTULA; PARAAORTIC LYMPH NODE; PROPORTIONAL HAZARDS MODEL; RECURRENCE RISK; STOMACH CANCER; SURVIVAL RATE; VERY ELDERLY; MIDDLE AGED; PROCEDURES; PROPHYLACTIC SURGICAL PROCEDURE; STOMACH NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; FEMALE; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; PROPHYLACTIC SURGICAL PROCEDURES; STOMACH NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893422075     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20130664     Document Type: Article

References (29)

1. Sasako M, Inoue M, Lin JT, Khor C, Yang HK, Ohtsu A. Gastric Cancer Working Group report. Jpn J Clin Oncol 2010; 40: i28-i37.
2. Sasako M, Saka M, Fukagawa T, Katai H, Sano T. Modern surgery for gastric cancer--Japanese perspective. Scand J Surg 2006; 95: 232-235.
3. Zhang CH, Zhan WH, He YL, Chen CQ, Huang MJ, Cai SR. Spleen preservation in radical surgery for gastric cardia cancer. Ann Surg Oncol 2007; 14: 1312-1319.
4. Kodera Y, Schwarz RE, Nakao A. Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials? J Am Coll Surg 2002; 195: 855-864.
5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
6. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006; 7: 309-315.
7. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11: 439-449.
8. Degiuli M, Sasako M, Calgaro M, Garino M, Rebecchi F, Mineccia M, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol 2004; 30: 303-308.
9. Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol 2007; 14: 317-328.
10. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
11. Sym SJ, Chang HM, Ryu MH, Lee JL, Kim TW, Yook JH, et al. Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. Ann Surg Oncol 2010; 17: 1024-1032.
12. Roviello F, Pedrazzani C, Marrelli D, Di Leo A, Caruso S, Giacopuzzi S, et al. Super-extended (D3) lymphadenectomy in advanced gastric cancer. Eur J Surg Oncol 2010; 36: 439-446.
13. Maeta M, Yamashiro H, Saito H, Katano K, Kondo A, Tsujitani S, et al. A prospective pilot study of extended (D3) and superextended para-aortic lymphadenectomy (D4) in patients with T3 or T4 gastric cancer managed by total gastrectomy. Surgery 1999; 125: 325-331.
14. de Manzoni G, Di Leo A, Roviello F, Marrelli D, Giacopuzzi S, Minicozzi AM, et al. Tumor site and perigastric nodal status are the most important predictors of para-aortic nodal involvement in advanced gastric cancer. Ann Surg Oncol 2011; 18: 2273-2280.
15. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008; 359: 453-462.
16. Kodera Y. Para-aortic lymph node dissection revisited: have we been neglecting a promising treatment option for gastric carcinoma? Eur J Surg Oncol 2010; 36: 447-448.
17. Tokunaga M, Ohyama S, Hiki N, Fukunaga T, Aikou S, Yamaguchi T. Can superextended lymph node dissection be justified for gastric cancer with pathologically positive paraaortic lymph nodes? Ann Surg Oncol 2010; 17: 2031-2036.
18. Fujimura T, Nakamura K, Oyama K, Funaki H, Fujita H, Kinami S, et al. Selective lymphadenectomy of para-aortic lymph nodes for advanced gastric cancer. Oncol Rep 2009; 22: 509-514.
19. Edge SB, Byrd DR, Compton CC, Fritz AG. Greene FL, Trotti A, et al. AJCC cancer staging manual. New York: Springer-Verlag; 2010.
20. Japanese Gastric Cancer A. Japanese Classification of Gastric Carcinoma-2nd English Edition. Gastric Cancer 1998; 1: 10-24.
21. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.
22. Schwarz RE, Smith DD, Keny H, IkléDN, Shibata SI, Chu DZ, et al. Impact of intraoperative radiation on postoperative and disease-specific outcome after pancreatoduodenectomy for adenocarcinoma: a propensity score analysis. Am J Clin Oncol 2003; 26: 16-21.
23. Park IH, Kim SY, Kim YW, Ryu KW, Lee JH, Lee JS, et al. Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement. Cancer Chemother Pharmacol 2011; 67: 127-136.
24. Kulig J, Popiela T, Kolodziejczyk P, Sierzega M, Szczepanik A. Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis of a multicenter, randomized, clinical trial. Am J Surg 2007; 193: 10-15.
25. Oyama K, Fushida S, Kinoshita J, Makino I, Nakamura K, Hayashi H, et al. Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and curative resection for gastric cancer with pathologically positive paraaortic lymph nodes. J Surg Oncol 2012; 105: 535-541.
26. Li JH, Zhang SW, Liu J, Shao MZ, Chen L. Review of clinical investigation on recurrence of gastric cancer following curative resection. Chin Med J 2012; 125: 1479-1495.
27. Zhang J, Chen RX, Cai J, Meng H, Wu GC, Zhang ZT, et al. Efficacy and safety of neoadjuvant chemotherapy with modified FOLFOX7 regimen on the treatment of advanced gastric cancer. Chin Med J 2012; 125: 2144-2150.
28. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379: 315-321.
29. Zhang C, Awasthi N, Schwarz MA, Schwarz RE. Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancer. J Surg Res 2013; 182: 227-234.